Skip to content

Effect of sumac powder on type 2 diabetes

Effect of powdered sumac (Rhus coriaria L) on glycemic control and insulin resistance in patients with type 2 diabetes.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014050410826N9
Enrollment
60
Registered
2014-06-14
Start date
2014-05-17
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Control group:take 2 cup low-fat yogurt daily without sumac for 3 months with lunch and dinner. Intervention 2: Intervention group: Daily for 3 months, 6 grams of powdered sumac two se
Placebo
Treatment - Drugs
Control group:take 2 cup low-fat yogurt daily without sumac for 3 months with lunch and dinner
Intervention group: Daily for 3 months, 6 grams of powdered sumac two servings (1 sachet 3 grams with lunch and one sachet 3 grams with dinner) was mixed with low-fat yogurt are used.

Sponsors

Research Council of Yazd University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: individuals between 30 and 60 years of their diabetes diagnosed diabetes center and at least 3 years of getting passed; lack of disorders and diseases of the liver and biliary and renal disorders; no professional athletes; not taking antioxidant supplements, selenium, zinc, beta carotene, omega-3 and at least 3 months before the study began; no alcohol; the willingness of patients to participate in the study; refusing to participate in other research projects; no change in dose or type of medication; do not use insulin. Exclusion criteria: those who consume less than 80 percent were crushed packages; people who have changed the type and dose of your medication; the patient's unwillingness to continue the study; start taking any antioxidant supplement; recent receiving insulin; to become pregnant during the study; diseases of liver and biliary and renal dysfunction during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fasting blood sugar. Timepoint: Before the intervention and after the intervention (3 months later). Method of measurement: Glucose oxidase method.;Glycosylated hemoglobin. Timepoint: Before the intervention and after the intervention (3 months later). Method of measurement: Spectrophotometric.;Insulin. Timepoint: Before the intervention and after the intervention (3 months later). Method of measurement: IRMA.;Insulin Resistance. Timepoint: Before the intervention and after the intervention (3 months later). Method of measurement: (glucose × insulin)/22.5.;Blood sugar levels two hours after a meal. Timepoint: Before the intervention and after the intervention (3 months later). Method of measurement: Glucose oxidase method.;Beta-cell function. Timepoint: Before the intervention and after the intervention (3 months later). Method of measurement: The amount of beta-cell function=(Fasting insulin × 20) / (fasting glucose, -3.5).

Secondary

MeasureTime frame
Added at 2016-11-29: HS-CRP. Timepoint: Added at 2016-11-29: At the beginning and the end of study period. Method of measurement: Added at 2016-11-29: 10 ml blood sample.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Najarzadeh

Yazd University of Medical Sciences

azadnajarzadeh@ssu.ac.ir+98 35 1624 0691

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026